G7 PPS LTD ACET SHELL 52E N/A 010000663

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a health professional,study report with the FDA on 2020-03-13 for G7 PPS LTD ACET SHELL 52E N/A 010000663 manufactured by Zimmer Biomet, Inc..

Event Text Entries

[183373768] (b)(4). Concomitant medical product(s): 010000857-g7 neutral e1 liner 36mm e-6592218; 192008-echo por fmrl nc 8x120mm-083280; 12-115120-cer bioloxd mod hd 36mm-2986013. Multiple mdr reports were filed for this event, please see associated reports: 0001825034 - 2020 - 01072, 0001825034 - 2020 - 01073. The human body consists of 4-5 liters of blood. Any type of blood loss has the potential to cause a complication however; it is usually the large, rapid blood loss during surgery or a trauma that will most likely cause complications. The amount of blood loss that may lead to intra and/or postoperative complications depends on the individual person and comorbidities, such as body mass index, gender, low pre-operative hemoglobin levels, medications and/or the presence of certain health conditions such as anemia, hemophilia, etc. , as well as duration of surgery. As blood loss effects are based on individual factors, treatment depends on the amount of blood loss, how quickly it was lost and the individuals health state. For larger blood loss, a blood transfusion or alternative may be needed. Hemorrhage is classified into 4 categories 1-4. Class i hemorrhage - minimal blood loss <750ml which would have minimal, if any impact on the patient, as the body will replenish a minimal blood loss without any intervention. Blood loss >750ml is considered to have larger impact and therefore the potential for medical intervention, i. E. Blood transfusion, or other alternative treatment. As the complaint indicates intraop blood loss greater than 750 ml, the patient had diagnosis of acute postop blood loss anemia and was symptomatic, medical intervention of blood transfusion (1 unit prbcs) was administered, and the patient's hospitalization was extended; therefore, complaint categories of medical: blood loss and medical: procedure related would be appropriate. Remains implanted.
Patient Sequence No: 1, Text Type: N, H10


[183373769] It was reported that a study patient had an initial left total hip arthroplasty that resulted with 800ml of blood loss. Subsequently, on postop day 1, the patient experienced tachycardia and fatigue that resulted in a blood transfusion and extended hospitalization. Attempts have been made and additional information on the reported event is unavailable at this time.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number0001825034-2020-01069
MDR Report Key9829262
Report SourceHEALTH PROFESSIONAL,STUDY
Date Received2020-03-13
Date of Report2020-03-13
Date of Event2020-02-05
Date Mfgr Received2020-02-18
Device Manufacturer Date2019-08-10
Date Added to Maude2020-03-13
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMS. CHRISTINA ARNT
Manufacturer Street56 E. BELL DR.
Manufacturer CityWARSAW IN 46582
Manufacturer CountryUS
Manufacturer Postal46582
Manufacturer Phone5745273773
Manufacturer G1ZIMMER BIOMET, INC.
Manufacturer Street56 E. BELL DRIVE
Manufacturer CityWARSAW IN 46582
Manufacturer CountryUS
Manufacturer Postal Code46582
Single Use3
Previous Use Code3
Removal Correction NumberNI
Event Type3
Type of Report3

Device Details

Brand NameG7 PPS LTD ACET SHELL 52E
Generic NamePROSTHESIS, HIP
Product CodePBI
Date Received2020-03-13
Model NumberN/A
Catalog Number010000663
Lot Number6578868
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerZIMMER BIOMET, INC.
Manufacturer Address56 E. BELL DRIVE WARSAW IN 46582 US 46582


Patients

Patient NumberTreatmentOutcomeDate
101. Hospitalization; 2. Required No Informationntervention 2020-03-13

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.